Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1CNS 1

Conditions

Solitary Fibrous Tumor, Pleural 1Small Cell Lung Carcinoma 1Recurrence 1Pleural Effusion, Malignant 1Mesothelioma, Malignant 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Docetaxel 8pembrolizumab 7Pemetrexed 5Carboplatin 5Erlotinib Hydrochloride 4toripalimab 3rociletinib 3fludarabine 3Radiosurgery 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Gemcitabine 3Etoposide 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3lorlatinib 2atezolizumab 2Vinorelbine 2Topotecan 2Radiotherapy 2Platinum 2Itraconazole 2Irinotecan 2Interleukin-2 2Cetuximab 2Albumin-Bound Paclitaxel 2vinflunine 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × rilotumumab × Thoracic × Clear all
NCT01233687 2017-06-22

AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer

University of Pittsburgh

Phase 1/2 Completed
49 enrolled 8 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡